JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

[Congenital nasolacrimal duct obstruction from an ophthalmologist's point of view : Causes, diagnosis and staged therapeutic concept].

HNO 2016 June
BACKGROUND: Congenital nasolacrimal duct obstruction (CNLDO) is one of the most frequent issues in pediatric ophthalmology. There are different therapeutic options, including conservative treatments as well as surgical interventions. These strategies can be classified using a staged therapeutic concept.

OBJECTIVE: What are the therapeutic strategies for CNLDO from an ophthalmologist's point of view?

METHODS: In this review, different kinds of CNLDO are described. Existing therapeutic interventions are dedicated to the different forms of CNLDO and summarized in a staged therapeutic concept.

RESULTS: CNLDO is not a homogeneous disease. Different and also combined pathologies exist. According to symptoms and localization of stenosis, different therapeutic interventions are available. The most common CNLDO manifestation is a persistent Hasner's membrane. If conservative approaches have failed, pressurized probing and syringing of the nasolacrimal duct is the method of choice. This can usually be done under local anesthesia. Since some children show persisting symptoms, other therapies (probing and syringing under general anesthesia with nasolacrimal duct intubation, external dacryocystorhinostomy) have to be considered. Here, dacryoendoscopy offers additional diagnostic and therapeutic options.

CONCLUSION: The precise classification of CNLDO and knowledge concerning possible therapeutic interventions are essential. Due to ongoing development of surgical approaches, an increasingly individualized therapy is possible. A gradual therapeutic regimen is available for CNLDO, which has to be adapted individually.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app